Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INSL3 as an Early Marker of Pubertal Activation: Evaluation of Its Potential Role as a New Biomarker in the Diagnosis of Central Precocious Puberty and Delayed Puberty.

NCT07859787 is registered in ClinicalTrials.gov with IRCCS Azienda Ospedaliero-Universitaria di Bologna as lead sponsor.

NCT NCT07859787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07859787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INSL3 as an Early Marker of Pubertal Activation: Evaluation of Its Potential Role as a New Biomarker in the Diagnosis of Central Precocious Puberty and Delayed Puberty.
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Overall status
Recruiting
Start date
October 2, 2026
Completion date
January 1, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

delayed puberty, precocious puberty, central